Revvity, Inc. (NYSE:RVTY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Revvity, Inc. (NYSE:RVTY) have been given an average rating of “Moderate Buy” by the twelve brokerages that are currently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $118.91.

Several equities research analysts recently issued reports on the stock. Wolfe Research assumed coverage on shares of Revvity in a research report on Wednesday, December 13th. They issued a “peer perform” rating on the stock. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $88.00 to $125.00 in a research report on Thursday, January 4th. KeyCorp raised their target price on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Stifel Nicolaus raised their target price on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Finally, Raymond James raised their target price on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd.

Revvity Price Performance

Revvity stock opened at $105.41 on Thursday. Revvity has a 12-month low of $79.50 and a 12-month high of $139.04. The stock has a market capitalization of $13.02 billion, a P/E ratio of 19.17, a P/E/G ratio of 2.68 and a beta of 1.10. The firm’s 50-day moving average is $105.80 and its two-hundred day moving average is $102.36. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The company had revenue of $695.90 million for the quarter. Equities analysts predict that Revvity will post 4.65 earnings per share for the current year.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.27%. Revvity’s payout ratio is currently 5.09%.

Insider Activity at Revvity

In related news, insider Prahlad R. Singh sold 21,217 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the sale, the insider now directly owns 92,801 shares in the company, valued at approximately $9,677,288.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Revvity

Hedge funds and other institutional investors have recently bought and sold shares of the business. Parkside Financial Bank & Trust purchased a new stake in Revvity during the 4th quarter worth approximately $25,000. Gladius Capital Management LP boosted its stake in Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after acquiring an additional 106 shares during the last quarter. Benjamin F. Edwards & Company Inc. acquired a new position in Revvity during the 4th quarter worth $27,000. CENTRAL TRUST Co bought a new stake in shares of Revvity in the 4th quarter worth about $27,000. Finally, ORG Partners LLC acquired a new stake in shares of Revvity in the 4th quarter valued at about $32,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.